HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Drug Channels News Roundup, Mid-June 2026: Biosimilar Development Barriers, Hospital Specialty Pharmacy Growth, Medicaid Incentives, Drug Pricing Tradeoffs, and the Prescription-Filling Process

By Bryce Platt, PharmD Summer officially starts this weekend! Consider doing a few of your lifting sets (or work meetings) outside. The healthier you are, the longer you'll be able to read our news roundups, so everybody wins! In this issue: A Leaky Biosimilar Funnel Reasons for Growth in Hospital S

By Drug Channels · Jun 17, 2026 · via Drug Channels

This is an aggregated industry headline. Read the full story at Drug Channels

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Pfizer's CFO Dave Denton will officially depart in August, leaving SVP of finance Cecile Guegan to take up his…
Jun 20, 2026
FDA warning slams Zoll Medical with multiple quality control and reporting violations
The WeekFierceBiotech ↗
Zoll Medical, the maker of devices and software focused on cardiopulmonary and respiratory conditions, was sla…
Jun 20, 2026
PwC: Biopharma M&A hits $65B in Q1, marking industry “full health”
The WeekBriefing
PwC says pharma and life sciences deals topped $65B in Q1 2026, led by big-ticket buys from Sun Pharma and GSK…
Jun 20, 2026